Comparing two drug combinations for advanced bowel cancer
Part of Cancer, Digestive system clinical trials.
This trial tests two different drug combinations for people with advanced bowel cancer that has a specific genetic change (RAS mutation) and has already been treated with one type of chemotherapy. The goal is to see if one combination works better than the other.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced bowel cancer that has spread and cannot be removed by surgery.
- Your cancer has a RAS mutation (a genetic change).
- You have already had one line of chemotherapy for advanced disease.
- You are able to do light activity and are not bedridden.
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial is testing a new combination of two oral cancer drugs (fruquintinib and S-1) in people with metastatic colorectal cancer who have already had at least one prior chemotherapy. The goal is to see if this combination helps shrink or slow the growth of tumors.
This trial tests whether the combination of fruquintinib with chemotherapy (trifluridine/tipiracil) works as well as or better than the current standard of bevacizumab with the same chemotherapy for advanced colorectal cancer that has spread. It is for patients who have already had several lines of treatment and are looking for new options.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
This study tests a combination of an immunotherapy drug, a targeted therapy, and a type of low-dose radiation before standard third-line treatment in patients with colorectal cancer that has spread to the liver. The goal is to see if this approach is safe and helps shrink tumors or slow cancer growth.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.